Arbor Center for EyeCare did not submit an investigational new drug (IND) application before beginning its clinical trial, the US Food and Drug Administration said. The agency posted the warning letter on 29 November.
The FDA inspected the Arbor Center’s clinical site during April as a part of the agency’s Bioresearch Monitoring Program, which looks after the health and safety of human test subjects.